190 related articles for article (PubMed ID: 36845546)
1. Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity.
Morais KLP; Ciccone L; Stura E; Alvarez-Flores MP; Mourier G; Driessche MV; Sciani JM; Iqbal A; Kalil SP; Pereira GJ; Marques-Porto R; Cunegundes P; Juliano L; Servent D; Chudzinski-Tavassi AM
Front Mol Biosci; 2023; 10():1072751. PubMed ID: 36845546
[TBL] [Abstract][Full Text] [Related]
2. A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate.
Lobba ARM; Alvarez-Flores MP; Fessel MR; Buri MV; Oliveira DS; Gomes RN; Cunegundes PS; DeOcesano-Pereira C; Cinel VD; Chudzinski-Tavassi AM
Front Mol Biosci; 2022; 9():936107. PubMed ID: 36052162
[TBL] [Abstract][Full Text] [Related]
3. Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
Pacheco MT; Berra CM; Morais KL; Sciani JM; Branco VG; Bosch RV; Chudzinski-Tavassi AM
PLoS One; 2014; 9(12):e111907. PubMed ID: 25479096
[TBL] [Abstract][Full Text] [Related]
4. Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.
Morais KL; Pacheco MT; Berra CM; Bosch RV; Sciani JM; Chammas R; de Freitas Saito R; Iqbal A; Chudzinski-Tavassi AM
Mol Cell Biochem; 2016 Apr; 415(1-2):119-31. PubMed ID: 27015684
[TBL] [Abstract][Full Text] [Related]
5. Specific role of cytoplasmic dynein in the mechanism of action of an antitumor molecule, Amblyomin-X.
Pacheco MT; Morais KL; Berra CM; Demasi M; Sciani JM; Branco VG; Bosch RV; Iqbal A; Chudzinski-Tavassi AM
Exp Cell Res; 2016 Jan; 340(2):248-58. PubMed ID: 26748183
[TBL] [Abstract][Full Text] [Related]
6. Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.
de Souza JG; Morais KL; Anglés-Cano E; Boufleur P; de Mello ES; Maria DA; Origassa CS; de Campos Zampolli H; Câmara NO; Berra CM; Bosch RV; Chudzinski-Tavassi AM
Oncotarget; 2016 Sep; 7(38):62255-62266. PubMed ID: 27566592
[TBL] [Abstract][Full Text] [Related]
7. Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates.
Chudzinski-Tavassi AM; Morais KL; Pacheco MT; Pasqualoto KF; de Souza JG
Biomed Pharmacother; 2016 Feb; 77():14-9. PubMed ID: 26796259
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity.
Maria DA; Will SEAL; Bosch RV; Souza JG; Sciani JM; Goldfeder MB; Rondon GG; Chudzinski-Tavassi AM
Toxicol Rep; 2019; 6():51-63. PubMed ID: 30581760
[TBL] [Abstract][Full Text] [Related]
9. Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo.
Branco VG; Iqbal A; Alvarez-Flores MP; Sciani JM; de Andrade SA; Iwai LK; Serrano SM; Chudzinski-Tavassi AM
Biochim Biophys Acta; 2016 Oct; 1864(10):1428-35. PubMed ID: 27479486
[TBL] [Abstract][Full Text] [Related]
10. Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells.
Schmidt MCB; Morais KLP; Almeida MES; Iqbal A; Goldfeder MB; Chudzinski-Tavassi AM
Cell Adh Migr; 2020 Dec; 14(1):129-138. PubMed ID: 30238848
[TBL] [Abstract][Full Text] [Related]
11. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis.
Drewes CC; Dias RY; Hebeda CB; Simons SM; Barreto SA; Ferreira JM; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2012 Sep; 60(3):333-40. PubMed ID: 22575283
[TBL] [Abstract][Full Text] [Related]
12. A new tick Kunitz type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system.
Chudzinski-Tavassi AM; De-Sá-Júnior PL; Simons SM; Maria DA; de Souza Ventura J; Batista IF; Faria F; Durães E; Reis EM; Demasi M
Toxicon; 2010 Dec; 56(7):1145-54. PubMed ID: 20570593
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro".
Akagi EM; Júnior PL; Simons SM; Bellini MH; Barreto SA; Chudzinski-Tavassi AM
Biomed Pharmacother; 2012 Feb; 66(1):64-9. PubMed ID: 22281290
[TBL] [Abstract][Full Text] [Related]
14. Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model.
Lichtenstein F; Iqbal A; de Lima Will SEA; Bosch RV; DeOcesano-Pereira C; Goldfeder MB; Chammas R; Trufen CEM; Morais KLP; de Souza JG; Natalino RJM; de Azevedo IJ; Nishiyama Junior MY; Oliveira U; Alves FIA; Araujo JM; Lobba ARM; Chudzinski-Tavassi AM
Sci Rep; 2020 Apr; 10(1):6388. PubMed ID: 32286411
[TBL] [Abstract][Full Text] [Related]
15. Structural findings and molecular modeling approach of a TFPI-like inhibitor.
Pasqualoto KF; Balan A; Barreto SA; Simons SM; Chudzinski-Tavassi AM
Protein Pept Lett; 2014 May; 21(5):452-7. PubMed ID: 24330085
[TBL] [Abstract][Full Text] [Related]
16. Post-transcriptional control of Amblyomin-X on secretion of vascular endothelial growth factor and expression of adhesion molecules in endothelial cells.
Drewes CC; Dias RY; Branco VG; Cavalcante MF; Souza JG; Abdalla DS; Chudzinski-Tavassi AM; Farsky SH
Toxicon; 2015 Jul; 101():1-10. PubMed ID: 25912945
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X.
Pavon LF; Capper D; Sibov TT; de Toledo SRC; Thomale UW; de Souza JG; Cabral FR; Berra CM; Silva da Costa MD; Mendonça Niçacio J; Dastoli PA; de Oliveira DM; Malheiros SMF; da Cruz EF; Malheiros JM; de Oliveira SM; Silva NS; Petrilli AS; Cappellano AM; Brunialti MC; Salomão R; de Paiva Neto MA; Chudzinski-Tavassi AM; Cavalheiro S
Sci Rep; 2019 Jul; 9(1):9973. PubMed ID: 31292491
[TBL] [Abstract][Full Text] [Related]
18. A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.
Ventura JS; Faria F; Batista IF; Simons SM; Oliveira DG; Morais KL; Chudzinski-Tavassi AM
Biomed Pharmacother; 2013 Apr; 67(3):192-6. PubMed ID: 23433900
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice.
Boufleur P; Sciani JM; Goldfeder M; Faria F; Branco V; Chudzinski-Tavassi AM
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):111-120. PubMed ID: 30132264
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
